Kardigan, Inc.
Update in progressKARD (NasdaqGM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Kardigan, Inc. is a biopharmaceutical company focused on medicines for cardiovascular diseases. It develops therapies targeting the underlying disease biology, including primary and secondary cardiomyopathies that lead to heart failure. Its proprietary R&D platform combines AI tools, real-world clinical data, and cardiac analytics to optimize trials, patient screening, and efficacy tracking. It uses Prolaio’s cardiovascular data platform with FDA-cleared algorithms. Kardigan engages in strategic licensing and acquisitions to broaden its pipeline, serving researchers and clinicians. Formerly EnCarda, Inc., it rebranded in December 2024. Founded in 2023 and based in Princeton, New Jersey.
Company score
- Sentiment
- 0.41
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.31
- Governance
- 0.15
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.12
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.27
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
No news articles are available for this company yet.
Unable to load company news.
You're all caught up!